RAVEL-TECHNOLOGIES
23.8.2022 19:28:16 CEST | Business Wire | Press release
Ravel Technologies S.A.S. (“Ravel'' or “Company”) proudly unveils several major patent-pending breakthroughs in Fully Homomorphic Encryption (FHE). Now 4 orders of magnitude faster than state-of-the-art, Ravel’s algorithmic discoveries are designed to make FHE finally scalable. The team is now building a sophisticated suite of fully encrypted technologies including the first fully encrypted SQL database equipped to query billions of encrypted data points, as well as advanced machine learning algorithms.
“Now that we have successfully overcome FHE’s biggest challenges, we will begin to put its uniquely powerful, protective capabilities to work,” explains Ravel CEO Mehdi Sabeg. “We have identified exciting opportunities in financial markets and privacy-preserving personalised advertising. We plan to address a full spectrum of vertically-diverse use cases, such as health data management, supply chain, financial services, and public services utilising our data sharing and analytics platform.”
Ravel includes a team of outstanding senior researchers in mathematics and is advised by Fields Medal Recipient Cedric Villani.
“Given the impressive, major algorithmic breakthroughs achieved by Ravel’s team, Ravel Fully Homomorphic Encryption (RHE) is orders of magnitude faster than state-of-the-art FHE schemes,” notes Villani. “With the continual increase of personal and industrial data being processed globally, privacy, and confidentiality protection are of paramount importance. Ravel’s breakthroughs bring an efficient and scalable answer to critical data privacy and security challenges.”
Ravel’s ability to process encrypted data with low latency and high throughput provides unparalleled de-identification capabilities that can also facilitate targeted advertisements with zero-knowledge of the consumer. Brands worldwide have long sought after exactly this solution, one that doesn’t infringe on the privacy of their users.
In the same fashion, Ravel can operate fully encrypted financial exchanges and remove certain market biases induced by plaintext data that can be exploited in the bidding process, for example. In this sector, confidentiality protection becomes increasingly important for large financial institutions starting to rely on transparent blockchain infrastructure.
“As we experienced during our Proof of Concept, Ravel has demonstrated that its technology can enable secure and efficient processing for high volumes of encrypted data,” BNP Paribas Group Chief Information Officer and Executive Committee Member Bernard Gavgani confirms. “They are well on their way to solving data sharing and analytics challenges in banking and finance for brands worldwide. We look forward to pursuing our collaboration.”
As Ravel strengthens its technological edge, the team is focused on scaling up its commercial growth, with a concentration on building out its presence across the US and European markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005745/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
